Compare Rent the Runway Inc (RENT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rent the Runway Inc vs Sanofi SA — how do they compare? Rent the Runway Inc trades at $1.76 (market cap $61.75M), while Sanofi SA trades at $40.04 (market cap $95.18B). The key difference: Sanofi SA is far larger — about 1541.4× Rent the Runway Inc's market cap, and Sanofi SA pays a 6.01% dividend while Rent the Runway Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rent the Runway Inc for 56 Days and Sanofi SA for 94 Days on average.
| RENT | SNY | |
|---|---|---|
Market Cap | $61.75M | $95.18B |
Volume | 193,323 | 2,995,646 |
Sector | Consumer Cyclical | Health |
52-Week High | $9.39 | $52.34 |
52-Week Low | $1.55 | $39.51 |
Typical Hold Time | 56 Days | 94 Days |
Enterprise Value | $228.75M | $114.48B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rent the Runway (RENT) trades at $1.77, up 5.36% today, with a bullish technical signal despite mixed indicators. The company reported Q2 2026 revenue growth of 20.8% year-over-year to $97.7 million, with improved gross margins, and appointed Paige Thomas as CEO in September 2026. However, it faces negative shareholder equity of -$182.5 million and a high debt-to-asset ratio of 139.62% as of 2025, though net losses have narrowed from -$212 million in 2022 to -$69.9 million in 2025.
The outlook is cautiously optimistic, with revenue growth and margin expansion offering potential upside, but significant financial leverage and ongoing legal investigations pose substantial risks. Analyst consensus is mixed, with 42% buy ratings, reflecting the balance between operational improvements and balance sheet concerns.
Sanofi (SNY) trades at $40.07, down 0.32% on the day, with a bearish technical signal from moving averages. The company reported strong earnings beats in recent quarters, with Q2 2026 EPS of $1.21 exceeding the $1.10 estimate. Revenue for 2025 reached $46.72 billion, with a net income margin of 16.72%. Recent news highlights a significant $8 billion immunology alliance expansion with Regeneron, signaling strategic growth initiatives.
The outlook is mixed; solid profitability and a strategic partnership provide upside potential, but a projected net income decline to $4.0 billion in 2026 and bearish technical indicators pose risks. Analyst sentiment is cautiously optimistic with a 44% buy rating, though investors should monitor execution of new collaborations and patent expiration impacts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rent the Runway Inc
Rent the Runway Inc is an e-commerce platform that allows users to rent, subscribe, or buy designer apparel and accessories.
Read more on RENT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
